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ABSTRACT
Recent genomic studies have revealed many kinds of genetic polymorphisms. Some genetic polymorphisms
have a correlation with allergic phenotypes, however there is only a statistical association without a precise mo-
lecular mechanism being demonstrated. Analysis of the molecular mechanisms from a proteomic perspective
should contribute to a better understanding of diseases and indicate possible therapeutic approaches. Recent
advances in identification and characterization of many immunological molecules have led to a shift to profiling
research, clinical proteomics, of already known factors. However, analysis of such biomarkers in allergies re-
quires methodological improvements because allergic reactions can be greatly influenced by subtle changes of
factors. These subtle changes cannot be detected by conventional techniques such as 2D-PAGE, and the
grammar behind the system is not well recognized by conventional proteomics. Examples of innovative meth-
ods useful for proteomic approaches to allergies are discussed here ; especially high throughput screening
and structural methods for allergy targeting.
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INTRODUCTION
Recent genomic studies have revealed many kinds of
genetic polymorphisms, some of them having a corre-
lation with allergic phenotypes. However , the find-
ings still remain basically statistical associations with-
out precise molecular mechanisms being demon-
strated. Analysis of the molecular mechanisms be-
tween the genotype and clinical symptoms should
contribute to better understandings of diseases and
indicate possible therapeutic approaches.
Several proteomic approaches have been described
in association with allergic diseases. One is an animal
experiment which found proteins closely related with
allergic airway inflammation , and another is two-
dimensional (2D)-PAGE analysis of allergens.1-3 2D-
PAGE analysis can indicate new possible allergens
associated with food allergies, which have not been
characterized by conventional 1D-PAGE. Such find-
ings by proteomics in allergy research would clarify
the molecular mechanism of the allergic reaction
with findings by genomics．
The word, proteomics, usually indicates searches
for understanding of the grammar behind biological
systems as a whole . However , recent advances in
identification and characterization of many immu-
nological molecules have led to shift toward profiling
research of already known factors such as cytoki-
nes. 4-6 Allergic reactions are mediated by many
kinds of factors. The specificity of allergic reactions is
regulated by recognition in the HLA : peptide and
TCR with many other factors subsequently modulat-
ing the responses. Many studies have shown that cy-
tokines participate in the induction and effecter
phases of inflammatory responses in allergies. Stud-
ies of the cytokine network are important for ascer-
taining candidates for drugs or as drug targets .
Hence, measurements of these cytokines are widely
used for monitoring immune responses in allergic
diseases.7,8
Clinical proteomics focuses on the study to eluci-
date biomarkers of disease, however, analysis of such
biomarkers in allergy requires innovative methodo-
logical improvements because allergies can be influ-
enced by subtle changes of factors that cannot be de-
tected by conventional techniques such as 2D-PAGE.
Furthermore, the grammar behind the systems can-
not be easily recognized by conventional proteomics．
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Fig. 1　Homogeneous assay of FLISA. a. Capture-antibody-
coated beads and secondary detection antibody with fluo-
rescence. b. A macro confocal imaging system with a heli-
um/neon laser focuses on and scans fluorescent-bound be- 
ads resting on the botoms of multiwel trays. Background flu-
orescence is minimal in relation to bead-bound fluorescence. 
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In the following we discuss examples of novel
methods useful for proteomic approaches to aller-
gies ; especially high throughput screening (HTS)
and structural methods for allergy targeting．
HIGH THROUGHPUT SCREENING METHOD
Enzyme-linked immunosorbent assay (ELISA) is an
established immunoassay used to quantify various cy-
tokines. However, conventional ELISA, is not readily
amenable for screening the large numbers of samples
required for proteomic screenings due to the fact that
it requires many processes and large quantities of an-
tibody . For proteomic research , high throughput
screening would benefit from an immunoassay that
requires minimal manipulation and uses only a small
amount of the compounds for screening. One such
ELISA based method, beads-based cytokine measure-
ment, has been developed and used for profiling of al-
lergic states.9
In addition to ELISA-based methods, fluorescence-
linked immunosorbent assay (FLISA) has been estab-
lished as a method for HTS.10 This system enables
high throughput measurements and could be applied
to the assessment of various factors such as cytoki-
nes or chemical mediators in allergic responses. A
typical FLISA method involves the preparation of
antibody-coated beads using streptavidin beads di-
luted in phosphate-buffered saline. A portion of the
biotinylated anti-factor X monoclonal antibody (mAb)
is added to the streptavidin beads solution and the
uncaptured antibodies removed. Fluorometric micro-
volume immunoassay for factor-X is performed with
an aliquot of samples placed into a 96-well plate. An
aliquot of the beads mixture (antibody beads) is con-
jugated with anti-factor-X mAb. Appropriate buffer is
then mixed with the sample or standard in each well
and incubated for several hours at room temperature
in the dark . After incubation , the 96-well plate is
scanned using a macro confocal imaging system (Fig.
1). The average fluorescence per bead is recorded. A
fluorescent microvolume assay technology instru-
ment consists of a detector integrated with a bar code
reader and a robotic plate handler that can accommo-
date large amounts of samples. A heliumneon laser
is used to map the topology of the microplate bottom,
and performs 256 scans across an area 1 mm × 1 mm
× 100 mm deep . The emitted fluorescence passes
through the same optical path as the excitation beam
and a dichroic beam splitter for detection by photom-
ultiplier tubes through filters.
The FLISA method is similar to a conventional
ELISA method, but has several advantages. ELISA re-
quires many incubation and wash steps, and also re-
quires large amount of reagents such as monoclonal
antibodies , making it practically unsuitable for
screening large numbers of samples. In addition to
this problem, ELISA can be influenced by tempera-
ture gradients in the microtiter plates. Studies using
microtitration plates have demonstrated that a tem-
perature gradient could exist between peripheral and
center wells of an ELISA plate ; a gradient that may
cause differences in an enzyme reaction between pe-
ripheral and center wells using microtitration plates,
the so called edge-effect.11,12 Samples must be han-
dled carefully in ELISA to prevent edge-effects ,
whereas, FLISA has no enzyme reaction at the calo-
rimetric phase, involving only the binding reaction of
the antibody, so that edge-effects should be smaller
in FLISA than ELISA . We obtained previous data
which found FLISA to be more reliable than ELISA,
and also that accurate screenings were very impor-
352 Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp
Kato Z et al.
Fig. 2　Structure of human IL-18. Schematic ribbon draw-
ing of the NMR structure of IL-18. 
tant in proteomics , especially for drug discover-
ies.13,14
To quantify the many factors in the proteomes of
different types of samples, FLISA is a more efficient
assay method than a conventional ELISA which in-
volves multiple incubation and washing steps, and re-
quires large amounts of antibodies . The FLISA
method is a homogeneous bead-based immunoassay
that requires no wash steps. Over 100-fold less cap-
tured antibody is required in FLISA than in a conven-
tional ELISA. However, the most striking difference
between the two methods is the time required for the
assay. Occupation time of a typical FLISA is about 1
hour, whereas a conventional ELISA will require sev-
eral more hours.15 A minimal time requirement is a
crucial factor for applications such as HTS in pro-
teomic research in allergology. FLISA is thus an at-
tractive method as it involves less hands-on time and
lower running costs.15
In immunological studies using FLISA, measure-
ments of interleukins and lymphocyte count in whole
blood have been reported.10,16 The beads-based sys-
tem of the FLISA is readily applicable to other plate-
based assays, such as non-radioactive kinase, phos-
phatase , and protease assays . A multiplexed bead-
based receptor-ligand binding assay has already been
demonstrated using FLISA.17,18 In addition, FLISA is
capable of detecting and quantifying fluorescence on
living cells, allowing for such diverse assays as apop-
tosis and cytotoxicity , and cellular immunoassays ,
and receptor ligand binding assays. 17-20 The FLISA
system can be adapted for HTS of large libraries of
proteomes, thus this system has a place in laborato-
ries that routinely perform multiple, repetitive assays.
STRUCTURAL APPROACHES
Immunological reactions such as production of IgE
are controlled by Th1 and Th2 cytokines. Disease
specific mutations for IgE suppressive factors such as
IL-12, IL-18, and IFN-gamma have been re-
vealed. 6,21,22 For example , we previously studied
IFN-gamma production from peripheral blood mono-
nuclear cells of patients with asthma or dermatitis.23
In most patients, both IL-18 and IL-12 induced the
same magnitude of IFN-gamma production . How-
ever , in some patients , IL-18 induced only a small
amount of IFN-gamma, while it was normal with IL-
12．
In patients whose IFN gamma production with IL-
18 is quite low, we found one amino acid deletion of
the receptor. Predominant expression of the deletion
of IL-18R alpha was associated with reduced IFN-
gamma production by IL-18 but not IL-12, and was
also associated with high serum IgE levels in chil-
dren.24 The actual effect of this deletion remains to be
clarified by further analyses of the system.
For analysis of the mechanisms, we used structural
biology techniques using multinuclear and multidi-
mensional NMR. NMR analyses were performed us-
ing 1D, 2D, 3D, and 4D NMR, and structural calcula-
tions and refinements revealed the structure of IL-18
at atomic resolution (Fig. 2).25
Sample preparation is usually performed with re-
combinant protein, which is produced in a heterolo-
gous organism such as E. coli 26,27 For example, the
15N-labeled and 15N-13C-labeled wild-type proteins
are expressed as a GST-fusion protein. Following pu-
rification by affinity chromatography, the GST tag is
removed by digestion with proteases . Samples for
NMR measurements typically consisted of 1―2 mM
protein in buffers with neutral pH and adequate salt,
in H2O2H2O or 2H2O．
NMR analyses are performed using high-field mag-
netic spectroscopy.28-32 NMR spectra can be acquired
at approximately 310K on spectroscopy with a mag-
netic field such as 800 MHz NMR spectrometer. For
assignment of the 1H, 13C and 15N resonances of the
backbone and the side-chains , a series of three-
dimensional experiments are performed . The
stereospecific assignment of methyl groups of the Val
and Leu residues was carried out. Distance restraints
are obtained from 15N, 15N-, 15N, 13C- or 13C, 13C-
resolved 4D NOESY experiments with an appropriate
mixing time.
Structural calculations were performed as the third
step. Initially, structure calculation and NOE peak as-
signment were performed in an iterative and manual
manner using a specific program for calculation.33-38
Backbone torsion angle restraints were derived from
3JHNHa of HNHA. The torsion angles c1 of phenyla-
lanine, tyrosine, and histidine, were estimated from
3JC’C and 3JNC coupling constants. After determin-
ing the global fold manually, an automated algorithm
can be used for the assignment of the remaining
NOE peaks, yielding meaningful NOE upper distance
Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp 353
Clinical Proteomics in Allergy
Fig. 4　Surface representation of IL-18 residues, the muta-
tions of which resulted in a substantial reduction in the ac-
tivity. Residues in sites I, I and II are in red, orange and 
blue, respectively. 
Fig. 5 Structure of the IL-18 : IL-18R alpha complex. IL-18 
residues in sites I, I and II are in red, orange and blue, res-
pectively.
Fig. 3　Distribution of the electrostatic potential on the 
solvent-accessible surface. Blue coresponds to positive po-
tential and red to negative potential. a, The IL-18 molecular 
is shown in the same orientation as for Figure 2 (left) and ro-
tated by 180 degrees about the vertical axis (right). b, Distri-
bution of the electrostatic potential on the solvent-accessible 
surface of IL-1beta.
a.
b.
restraints. With these restraints, final structures were
calculated using the refinement program . At this
stage, hydrogen bond restraints from the slowly ex-
changing backbone amides can be added as distance
restraints for N-O and for HN-O atom pairs respec-
tively . Nonstereospecifically assigned protons were
treated as a floating chirality. Usually, a total of 100
structures were refined and the 20 lowest energy
structures were analyzed using structure verification
software．
The determined IL-18 structure has the same pro-
tein folding as that of IL-1, but IL-18 is distinctively
different from IL-1 in its functional properties.25,39-44
This means that the presence of these structural dif-
ferences reflects their functional differences. Struc-
tural comparison between the two showed relatively
large differences in three parts. Although the folding
of the proteins were quite similar, distribution of the
electrostatic surface potentials between the two were
very different (Fig. 3). These differences at an atomic
level serve as the factors for molecular discrimina-
tion.
When we mapped the critical residues for the bio-
logical activity on the surface of the structure , we
found that they formed three distinct sites, named as
sites 1, 2, and 3 (Fig. 4). From other experimental
findings such as protein-protein interactions , the
ligand, IL-18, was seen to bind to IL-18Ralpha using
sites 1 and 2, but not site 3.25,45-51 When we viewed its
3-D structure, we could see that sites 1 and 2 were
covered by a receptor with atomic interactions ,
whereas site 3 was completely free (Fig. 5).
Previously reported genetic polymorphisms are not
involved within the three sites. One of the identified
coding SNPs , R 210H , had interactions with the
ligand, IL-18, suggesting an effect for binding affin-
ity.25,52 The deletion of alanine 317 closely associates
with the functional abnormality in IL-18 signaling.24,25
Our modeling study indicates that the deletion
should not change the overall structure, but make the
link shorter at a point just before the transmembrane
domain by approximately five angstroms.
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Fig. 7　Atomic scale strategy for proteomics toward therapeutic approaches against alergy.
Structure-based 
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Fig. 6　New classifications for interleukins. The major gro-
up is alpha helix bundle types, with IL-8 a member of the 
chemokines from its structural properties in addition to its 
functional properties. The new class is the beta-trefoil gro-
up, and there are several orphan classes.
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Taken together with other experimental data, we
could ascertain that a tertiary complex formation
could be achieved by interactions with receptor alpha
at sites 1 and 2. For receptor beta, site 3 and addi-
tional interactions between receptors would be in-
volved . 25,51 The deletion should effect the signal
transduction modifying the alignment of the intracel-
lular domains. Other SNPs on 232 can also have a
functional change on their receptor- receptor interac-
tions.25,51,52
From these data, we can now classify interleukins
by their structures (Fig. 6). Before our structural de-
termination of IL-18, several structures had been re-
vealed. Our study proposed a new structural class ,
beta- trefoil interleukins , IL-1 and IL-18. The addi-
tional structural investigations by our group and
other research groups have shown a catalogue of in-
terleukins . From these data , we have postulated a
new classification for interleukins. The major group is
alpha helix bundle types, with IL-8 being a member of
the chemokines which is based on its structural prop-
erties in addition to its functional properties. The new
class is the beta-trefoil group also in addition to other
orphan classes.53-55
TOWARD THERAPEUTIC APPROACHES
From a therapeutic aspect, the atomic interactions be-
tween ligand and receptors should present a target
for drugs. For example, in this IL-18 system, the over-
all binding surface is too large to be a target, but for
example , site 1 residue aspartic acid has a critical
force for binding.25 It has a complementary charge in-
teraction with arginine of the receptor residue. The
alanine mutant protein showed a significant loss of
biological and receptor binding activities. This muta-
tion was shown to have an effect related to the reduc-
tion of local surface negative potential , but not in
other regions. Thus, we can focus on a pinpoint inter-
action as a target for development of drugs such as
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antagonists.
Structural design of therapeutic molecules can be
done at three levels : protein, peptide, and for low
molecular weight chemicals. At the protein level, we
can change the protein function including the stable
agonist or antagonist by protein engineering.57 At the
peptide level, several successful observations are pos-
sible . For example , IL-1 receptor and antagonistic
peptide complex structures have been studied.58 This
is an important lead compound for drug determina-
tions. For screening of chemicals, we are now per-
forming virtual ligand screening instead of actual ac-
tivity assay . HTS methods such as FLISA , as de-
scribed above, will enhance the second step involving
the actual screening.
Structural analysis of molecular recognition can
help us to discuss disease mechanisms including
genotype-phenotype correlations or therapeutic ap-
proaches on the scale of drug molecules. This atomic
scale strategy should bring with it great contributions
to understanding the pathogenesis of allergies, and to
develop therapies against allergy (Fig. 7).
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